0910-AH56 202104 Unified Agenda of Federal Regulatory and Deregulatory Actions 0910 Food and Drug Administration FDA 0900 Department of Health and Human Services HHS Certain Requirements Regarding Prescription Drug Marketing (203 Amendment)

The Food and Drug Administration (FDA) is amending the regulations at 21 CFR 203 to remove provisions no longer in effect and incorporate conforming changes following enactment of the Drug Supply Chain Security Act (DSCSA). In this proposed rulemaking, the Agency is amending the regulations to clarify provisions and avoid causing confusion with the new standards for wholesale distribution established by DSCSA.

]]> Substantive, Nonsignificant Previously Published in The Unified Agenda Proposed Rule Stage No No 21 CFR 203 Pub. L. 113-54 No NPRM 09/00/2021 Yes Businesses State Undetermined No Yes No Aaron Weisbuch Regulatory Counsel 0910 Food and Drug Administration FDA 301 796-9362 aaron.weisbuch@fda.hhs.gov Center for Drug Evaluation and Research, Building 51, Room 4261, 10903 New Hampshire Avenue, Silver Spring MD 20993